Q1 2024 EPS Estimates for Oncternal Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:ONCT)

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) – Research analysts at HC Wainwright upped their Q1 2024 earnings per share estimates for Oncternal Therapeutics in a note issued to investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($3.30) per share for the quarter, up from their previous estimate of ($3.52). HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Oncternal Therapeutics’ current full-year earnings is ($12.03) per share. HC Wainwright also issued estimates for Oncternal Therapeutics’ Q2 2024 earnings at ($3.42) EPS, Q3 2024 earnings at ($3.63) EPS, Q4 2024 earnings at ($3.68) EPS and FY2024 earnings at ($14.04) EPS.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its earnings results on Thursday, March 7th. The company reported ($3.11) EPS for the quarter, missing the consensus estimate of ($3.09) by ($0.02). Oncternal Therapeutics had a negative return on equity of 95.87% and a negative net margin of 5,029.17%. The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same quarter in the previous year, the firm earned ($4.00) earnings per share.

Separately, StockNews.com assumed coverage on Oncternal Therapeutics in a research note on Wednesday. They set a “hold” rating for the company.

Oncternal Therapeutics Stock Down 3.9 %

Oncternal Therapeutics stock opened at $8.60 on Thursday. Oncternal Therapeutics has a 52 week low of $5.57 and a 52 week high of $13.14. The business has a 50-day simple moving average of $8.90 and a 200 day simple moving average of $8.11. The stock has a market cap of $23.13 million, a price-to-earnings ratio of -0.64 and a beta of 1.26.

Insider Activity at Oncternal Therapeutics

In other Oncternal Therapeutics news, Director Robert James Wills acquired 3,086 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average cost of $8.96 per share, with a total value of $27,650.56. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $89,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have acquired 10,714 shares of company stock valued at $92,736. 8.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Oncternal Therapeutics

A number of institutional investors have recently bought and sold shares of ONCT. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Oncternal Therapeutics in the 1st quarter worth $585,000. Vanguard Group Inc. increased its stake in Oncternal Therapeutics by 9.0% in the 1st quarter. Vanguard Group Inc. now owns 2,325,515 shares of the company’s stock worth $3,232,000 after buying an additional 192,189 shares in the last quarter. Renaissance Technologies LLC increased its stake in Oncternal Therapeutics by 44.4% in the 1st quarter. Renaissance Technologies LLC now owns 543,800 shares of the company’s stock worth $756,000 after buying an additional 167,268 shares in the last quarter. Mirabella Financial Services LLP purchased a new stake in Oncternal Therapeutics in the 1st quarter worth $38,000. Finally, UBS Group AG increased its stake in Oncternal Therapeutics by 1,373.8% in the 2nd quarter. UBS Group AG now owns 166,298 shares of the company’s stock worth $184,000 after buying an additional 155,014 shares in the last quarter. 16.05% of the stock is owned by institutional investors.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.